Expression analysis of Ubc9, the single small ubiquitin-like modifier (SUMO) E2 conjugating enzyme, in normal and malignant tissues

Human Pathology

Volumn 41, Issue 9, 2010, Pages 1286-1298

  Moschos, Stergios J ^a   Jukic, Drazen M ^a   Athanassiou, Charalambos ^b   Bhargava, Rohit ^a   Dacic, Sanja ^a   Wang, Xiaolei ^a   Kuan, Shih Fan ^a   Fayewicz, Shelley L ^a   Galambos, Csaba ^a   Acquafondata, Marie ^a   Dhir, Rajiv ^a   Becker, Dorothea ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

Cancer; Immune infiltrate; Immunohistochemistry; Tissue microarray; Ubc9

Indexed keywords

PROTEIN UBC9; SUMO 2 PROTEIN;

ADENOCARCINOMA; ARTICLE; BREAST CANCER; CANCER GRADING; CANCER STAGING; COLON; COLON CANCER; COMPARATIVE STUDY; CONTROLLED STUDY; GLEASON SCORE; HUMAN; HUMAN TISSUE; LUNG CANCER; PRIMARY TUMOR; PROSTATE CANCER; PROTEIN EXPRESSION; TISSUE MICROARRAY;

FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; NEOPLASM METASTASIS; NEOPLASMS; TISSUE ARRAY ANALYSIS; UBIQUITIN-CONJUGATING ENZYMES;

EID: 77955924786     PISSN: 00468177     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humpath.2010.02.007     Document Type: Article

References (32)

1. Moschos S.J., and Mo Y.Y. Role of SUMO/Ubc9 in DNA damage repair and tumorigenesis J Mol Histol 37 2006 309 319
2. Nacerddine K., Lehembre F., and Bhaumik M. The SUMO pathway is essential for nuclear integrity and chromosome segregation in mice Dev Cell 9 2005 769 779
3. Lin D., Tatham M.H., Yu B., Kim S., Hay R.T., and Chen Y. Identification of a substrate recognition site on Ubc9 J Biol Chem 277 2002 21740 21748
4. Sentis S., Le Romancer M., Bianchin C., Rostan M.C., and Corbo L. Sumoylation of the estrogen receptor alpha hinge region regulates its transcriptional activity Mol Endocrinol 19 2005 2671 2684
5. Murakami H., and Arnheiter H. Sumoylation modulates transcriptional activity of MITF in a promoter-specific manner Pigment Cell Res 18 2005 265 277
6. Vatsyayan J., Qing G., Xiao G., and Hu J. SUMO1 modification of NF-kappaB2/p100 is essential for stimuli-induced p100 phosphorylation and processing EMBO Rep 9 2008 885 890
7. Smolen G.A., Vassileva M.T., Wells J., Matunis M.J., and Haber D.A. SUMO-1 modification of the Wilms' tumor suppressor WT1 Cancer Res 64 2004 7846 7851
8. Poukka H., Karvonen U., Janne O.A., and Palvimo J.J. Covalent modification of the androgen receptor by small ubiquitin-like modifier 1 (SUMO-1) Proc Natl Acad Sci U S A 97 2000 14145 14150
9. Moschos S.J., Smith A.P., and Mandic M. SAGE and antibody array analysis of melanoma-infiltrated lymph nodes: identification of Ubc9 as an important molecule in advanced-stage melanomas Oncogene 26 2007 4216 4225
10. Mo Y.Y., Yu Y., Theodosiou E., Rachel Ee P.L., and Beck W.T. A role for Ubc9 in tumorigenesis Oncogene 24 2005 2677 2683
11. Wu F., Zhu S., Ding Y., Beck W.T., and Mo Y.Y. MicroRNA-mediated regulation of Ubc9 expression in cancer cells Clin Cancer Res 15 2009 1550 1557
12. McDoniels-Silvers A.L., Nimri C.F., Stoner G.D., Lubet R.A., and You M. Differential gene expression in human lung adenocarcinomas and squamous cell carcinomas Clin Cancer Res 8 2002 1127 1138
13. Geletu M., Balkhi M.Y., and Peer Zada A.A. Target proteins of C/EBPalphap30 in AML: C/EBPalphap30 enhances sumoylation of C/EBPalphap42 via up-regulation of Ubc9 Blood 110 2007 3301 3309
14. Han J.Y., Lee G.K., and Yoo S.Y. Association of SUMO1 and UBC9 genotypes with tumor response in non-small-cell lung cancer treated with irinotecan-based chemotherapy Pharmacogenomics J 10 2010 86 93
15. Detre S., Saclani Jotti G., and Dowsett M. A "quickscore" method for immunohistochemical semiquantitation: validation for oestrogen receptor in breast carcinomas J Clin Pathol 48 1995 876 878
16. Hugh J., Hanson J., and Cheang M.C. Breast cancer subtypes and response to docetaxel in node-positive breast cancer: use of an immunohistochemical definition in the BCIRG 001 trial J Clin Oncol 27 2009 1168 1176
17. Sorlie T., Perou C.M., and Tibshirani R. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications Proc Natl Acad Sci U S A 98 2001 10869 10874
18. Ronen O., Malone J.P., and Kay P. Expression of a novel marker, Ubc9, in squamous cell carcinoma of the head and neck Head Neck 31 2009 845 855
19. Dunnebier T., Bermejo J.L., and Haas S. Common variants in the UBC9 gene encoding the SUMO-conjugating enzyme are associated with breast tumor grade Int J Cancer 125 2009 596 602
20. Driscoll J.J., Pelluru D., and Lefkimmiatis K. The sumoylation pathway is dysregulated in multiple myeloma and is associated with adverse patient outcome Blood 2009 [Epub ahead of print]
21. Mo Y.Y., Yu Y., Ee P.L., and Beck W.T. Overexpression of a dominant-negative mutant Ubc9 is associated with increased sensitivity to anticancer drugs Cancer Res 64 2004 2793 2798
22. Yamamoto H., Ihara M., Matsuura Y., and Kikuchi A. Sumoylation is involved in beta-catenin-dependent activation of Tcf-4 EMBO J 22 2003 2047 2059
23. van de Wetering M., Sancho E., and Verweij C. The beta-catenin/TCF-4 complex imposes a crypt progenitor phenotype on colorectal cancer cells Cell 111 2002 241 250
24. Poukka H., Aarnisalo P., Karvonen U., Palvimo J.J., and Janne O.A. Ubc9 interacts with the androgen receptor and activates receptor-dependent transcription J Biol Chem 274 1999 19441 1944?
25. Lu Z., Wu H., and Mo Y.Y. Regulation of bcl-2 expression by Ubc9 Exp Cell Res 312 2006 1865 1875
26. Yan J., Yang X.P., Kim Y.S., Joo J.H., and Jetten A.M. RAP80 interacts with the SUMO-conjugating enzyme UBC9 and is a novel target for sumoylation Biochem Biophys Res Commun 362 2007 132 138
27. Morris J.R., Boutell C., and Keppler M. The SUMO modification pathway is involved in the BRCA1 response to genotoxic stress Nature 462 2009 886 890
28. Xu J., Watkins T., Reddy A., Reddy E.S., and Rao V.N. A novel mechanism whereby BRCA1/1a/1b fine tunes the dynamic complex interplay between SUMO-dependent/independent activities of Ubc9 on E2-induced ERalpha activation/repression and degradation in breast cancer cells Int J Oncol 34 2009 939 949
29. Pascual G., Fong A.L., and Ogawa S. A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-gamma Nature 437 2005 759 763
30. Garaude J., Farras R., and Bossis G. SUMOylation regulates the transcriptional activity of JunB in T lymphocytes J Immunol 180 2008 5983 5990
31. Leavenworth J.W., Ma X., Mo Y.Y., and Pauza M.E. SUMO conjugation contributes to immune deviation in nonobese diabetic mice by suppressing c-Maf transactivation of IL-4 J Immunol 183 2009 1110 1119
32. Lee J.H., Park S.M., and Kim O.S. Differential SUMOylation of LXRalpha and LXRbeta mediates transrepression of STAT1 inflammatory signaling in IFN-gamma-stimulated brain astrocytes Mol Cell 35 2009 806 817